ARTICLE | Emerging Company Profile
Company is ditching animal models and designing biopsy-free trials
By Richard Guy, Biopharma Analyst
February 8, 2024 9:57 PM UTC
Liver disease company Ochre has a three-part system for validating siRNA therapeutic targets that relies entirely on human cells and tissues, sidestepping the problems of animal models. The company is also rethinking clinical trials, hoping to get proof-of-concept data quickly without using biopsy-based endpoints.
Based in Oxford, U.K., with additional labs in Taipei and New York, Ochre Bio Ltd. has raised $40 million across seed and series A rounds since its 2019 founding…